M Rizell, R Hultborn, P Bernhardt, J Svensson, M Sternby Eilard, O ...

More documents

Recommendations

Info

Table 1a continued. Hepatocellular carcinoma Outcome: Survival Study Publication Year Keppke Kooby Kulik Lau Salem Salem Young Design Number of patients Survival Median (months) Survival 1-year Survival 2-year Survival 3-year Quality of study 2007 Case series 42 14.4*** - - - - 2009 Retrospective controlled? cohort n= 44 TACE n= 27 90 Y-RE 6 6 20% (9) 16% (4) 2008 Case series 108 14.6*** - - - - 1998 Case series 71 9.4 - - - - 2009 Prospective cohort 2005 Prospective cohort 2007 Retrospective cohort Abbreviations: TACE = transarterial chemoembolization 90 Y-RE = Yttrium-90 radioembolization Fotnot: * data extracted from Kaplan-Meier-curves, ** survival 6 months *** recalculated 291 10.9*** - - - - - - - - 43 18.9*** - - - - 41 18.1*** - - - - -
Table 1b. Hepatocellular carcinoma Outcome: Tumour response Study Carr Lewandowski Steel Carr Geschwind Goin Goin Publication year 2010 Nonrandomized, controlled 2010 Nonrandomized, controlled 2003 Nonrandomized, controlled Design Number of patients n= 691 TACE n= 99 90 Y-RE n= 43 TACE n= 43 90 Y-RE n= 43 TACE n= 43 90 Y-RE n= 13 TACE n= 15 90 Y-RE Tumor evaluation TTP (months) WHO - - WHO EASL 2004 Cohort 65 Own criteria - - 19.6 48.6 - - - - CR (%) 5 3 0 0 17 47 - - PR (%) 55 33/3 8 37 61 54 39 - - SD (%) 29 35 49 37 - - - - PD (%) 11 23 14 2 - - - - Quality of study Moderate -low Moderate Low - - 38.4 - - - 2004 Case series 80 - - - - - - - 2005 Case series 121 - - - - - - - 2005 Case series 88 - - - - - - -
Page 1 and 2: Health Technology Assessment HTA-ra
Page 3 and 4: Quality assurance process External
Page 5 and 6: Utlåtande och sammanfattande bedö
Page 7 and 8: Levermetastaser från kolorektal ca
Page 9 and 10: Question at issue: Does treatment w
Page 11 and 12: Which health technology or method w
Page 13 and 14: Both of these treatments for HCC ha
Page 15 and 16: locally administered treatment is t
Page 17 and 18: The reporting of adverse effects an
Page 19 and 20: Ethical aspects 7a. Ethical consequ
Page 21 and 22: Economy 9a. Present costs of curren
Page 23 and 24: assumed that this treatment would b
Page 25 and 26: Summary of the Health Technology As
Page 27 and 28: APPENDIX 1 - SEARCH STRATEGY, STUDY
Page 29 and 30: CRD 2009-12-16 Yttrium OR SIR-spher
Page 31 and 32: References Included studies: Hepato
Page 33 and 34: Kennedy AS, Coldwell D, Nutting C,
Page 35 and 36: Sangro B, Gil-Alzugaray B, Rodrigue
Page 37: Table 1a. Hepatocellular carcinoma
Page 41 and 42: Table 1c. Hepatocellular carcinoma
Page 43 and 44: Table 2a. Hepatic metastases from c
Page 45 and 46: Appendix 3 Ref nr Study Reason for
Page 47: Sahlgrenska Universitetssjukhuset,

M Rizell, R Hultborn, P Bernhardt, J Svensson, M Sternby Eilard, O ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?